{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:56:17Z","timestamp":1794851777114,"version":"4.9.1"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41577-022-00800-6","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:35:49Z","timestamp":1669394149000},"page":"397-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Gene therapy for inborn errors of immunity: past, present and future"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4025-5983","authenticated-orcid":false,"given":"Alain","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"800_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.175.4025.949","volume":"175","author":"T Friedmann","year":"1972","unstructured":"Friedmann, T. & Roblin, R. Gene therapy for human genetic disease? Science 175, 949\u2013955 (1972).","journal-title":"Science"},{"key":"800_CR2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1126\/science.3287617","volume":"240","author":"H Varmus","year":"1988","unstructured":"Varmus, H. Retroviruses. Science 240, 1427\u20131435 (1988).","journal-title":"Science"},{"key":"800_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/310476a0","volume":"310","author":"DA Williams","year":"1984","unstructured":"Williams, D. A., Lemischka, I. R., Nathan, D. G. & Mulligan, R. C. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310, 476\u2013480 (1984).","journal-title":"Nature"},{"key":"800_CR4","first-page":"2895","volume":"6","author":"AD Miller","year":"1986","unstructured":"Miller, A. D. & Buttimore, C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell Biol. 6, 2895\u20132902 (1986).","journal-title":"Mol. Cell Biol."},{"key":"800_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s10875-021-00980-1","volume":"41","author":"SG Tangye","year":"2021","unstructured":"Tangye, S. G. et al. The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS Committee. J. Clin. Immunol. 41, 666\u2013679 (2021).","journal-title":"J. Clin. Immunol."},{"key":"800_CR6","doi-asserted-by":"publisher","first-page":"15061","DOI":"10.1038\/nrdp.2015.61","volume":"1","author":"A Fischer","year":"2015","unstructured":"Fischer, A., Notarangelo, L. D., Neven, B., Cavazzana, M. & Puck, J. M. Severe combined immunodeficiencies and related disorders. Nat. Rev. Dis. Prim. 1, 15061 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"800_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jaci.2020.10.020","volume":"147","author":"R Currier","year":"2021","unstructured":"Currier, R. & Puck, J. M. SCID newborn screening: what we\u2019ve learned. J. Allergy Clin. Immunol. 147, 417\u2013426 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR8","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","volume":"2","author":"RA Gatti","year":"1968","unstructured":"Gatti, R. A., Meuwissen, H. J., Allen, H. D., Hong, R. & Good, R. A. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2, 1366\u20131369 (1968).","journal-title":"Lancet"},{"key":"800_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/NEJMoa1401177","volume":"371","author":"SY Pai","year":"2014","unstructured":"Pai, S. Y. et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N. Engl. J. Med. 371, 434\u2013446 (2014).","journal-title":"N. Engl. J. Med."},{"key":"800_CR10","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.jaci.2021.10.017","volume":"149","author":"AC Lankester","year":"2022","unstructured":"Lankester, A. C. et al. Hematopoietic cell transplantation in severe combined immunodeficiency: the SCETIDE 2006-2014 European cohort. J. Allergy Clin. Immunol. 149, 1744\u20131754 e1748 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1056\/NEJMcibr1713238","volume":"378","author":"S Sarantopoulos","year":"2018","unstructured":"Sarantopoulos, S. Allogeneic stem-cell transplantation \u2014 a T-cell balancing ACT. N. Engl. J. Med. 378, 480\u2013482 (2018).","journal-title":"N. Engl. J. Med."},{"key":"800_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1126\/science.288.5466.669","volume":"288","author":"M Cavazzana-Calvo","year":"2000","unstructured":"Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669\u2013672 (2000).","journal-title":"Science"},{"key":"800_CR13","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1126\/science.1070104","volume":"296","author":"A Aiuti","year":"2002","unstructured":"Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410\u20132413 (2002).","journal-title":"Science"},{"key":"800_CR14","first-page":"9","volume":"13","author":"JM Vossen","year":"1973","unstructured":"Vossen, J. M. et al. Successful treatment of an infant with severe combined immunodeficiency by transplantation of bone marrow cells from an uncle. Clin. Exp. Immunol. 13, 9\u201320 (1973).","journal-title":"Clin. Exp. Immunol."},{"key":"800_CR15","doi-asserted-by":"publisher","first-page":"7576","DOI":"10.1073\/pnas.84.21.7576","volume":"84","author":"G de Saint Basile","year":"1987","unstructured":"de Saint Basile, G. et al. Close linkage of the locus for X chromosome-linked severe combined immunodeficiency to polymorphic DNA markers in Xq11-q13. Proc. Natl Acad. Sci. USA 84, 7576\u20137579 (1987).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1126\/science.1631559","volume":"257","author":"T Takeshita","year":"1992","unstructured":"Takeshita, T. et al. Cloning of the gamma chain of the human IL-2 receptor. Science 257, 379\u2013382 (1992).","journal-title":"Science"},{"key":"800_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0092-8674(93)90167-O","volume":"73","author":"M Noguchi","year":"1993","unstructured":"Noguchi, M. et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147\u2013157 (1993).","journal-title":"Cell"},{"key":"800_CR18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","volume":"50","author":"WJ Leonard","year":"2019","unstructured":"Leonard, W. J., Lin, J. X. & O\u2019Shea, J. J. The gammac family of cytokines: basic biology to therapeutic ramifications. Immunity 50, 832\u2013850 (2019).","journal-title":"Immunity"},{"key":"800_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","volume":"377","author":"P Macchi","year":"1995","unstructured":"Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65\u201368 (1995).","journal-title":"Nature"},{"key":"800_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.270.5237.797","volume":"270","author":"SM Russell","year":"1995","unstructured":"Russell, S. M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797\u2013800 (1995).","journal-title":"Science"},{"key":"800_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/3877","volume":"20","author":"A Puel","year":"1998","unstructured":"Puel, A., Ziegler, S. F., Buckley, R. H. & Leonard, W. J. Defective IL7R expression in T\u2212B+NK+ severe combined immunodeficiency. Nat. Genet. 20, 394\u2013397 (1998).","journal-title":"Nat. Genet."},{"key":"800_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1073\/pnas.92.2.377","volume":"92","author":"JP DiSanto","year":"1995","unstructured":"DiSanto, J. P., Muller, W., Guy-Grand, D., Fischer, A. & Rajewsky, K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc. Natl Acad. Sci. USA 92, 377\u2013381 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1084\/jem.189.3.563","volume":"189","author":"JP Di Santo","year":"1999","unstructured":"Di Santo, J. P. et al. The common cytokine receptor gamma chain and the pre-T cell receptor provide independent but critically overlapping signals in early alpha\/beta T cell development. J. Exp. Med. 189, 563\u2013574 (1999).","journal-title":"J. Exp. Med."},{"key":"800_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ng0796-290","volume":"13","author":"R Hirschhorn","year":"1996","unstructured":"Hirschhorn, R. et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat. Genet. 13, 290\u2013295 (1996).","journal-title":"Nat. Genet."},{"key":"800_CR25","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJM199611213352104","volume":"335","author":"V Stephan","year":"1996","unstructured":"Stephan, V. et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N. Engl. J. Med. 335, 1563\u20131567 (1996).","journal-title":"N. Engl. J. Med."},{"key":"800_CR26","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1182\/blood-2008-04-153361","volume":"112","author":"C Speckmann","year":"2008","unstructured":"Speckmann, C. et al. Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency. Blood 112, 4090\u20134097 (2008).","journal-title":"Blood"},{"key":"800_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10875-015-0174-0","volume":"35","author":"AP Hsu","year":"2015","unstructured":"Hsu, A. P. et al. IL2RG reversion event in a common lymphoid progenitor leads to delayed diagnosis and milder phenotype. J. Clin. Immunol. 35, 449\u2013453 (2015).","journal-title":"J. Clin. Immunol."},{"key":"800_CR28","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3324\/haematol.2012.077511","volume":"98","author":"TW Kuijpers","year":"2013","unstructured":"Kuijpers, T. W. et al. A reversion of an IL2RG mutation in combined immunodeficiency providing competitive advantage to the majority of CD8+ T cells. Haematologica 98, 1030\u20131038 (2013).","journal-title":"Haematologica"},{"key":"800_CR29","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.ebiom.2020.102961","volume":"59","author":"P Kury","year":"2020","unstructured":"Kury, P. et al. Long-term robustness of a T-cell system emerging from somatic rescue of a genetic block in T-cell development. EBioMedicine 59, 102961 (2020).","journal-title":"EBioMedicine"},{"key":"800_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1073\/pnas.97.1.274","volume":"97","author":"P Bousso","year":"2000","unstructured":"Bousso, P. et al. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc. Natl Acad. Sci. USA 97, 274\u2013278 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0139-x","author":"P Revy","year":"2019","unstructured":"Revy, P., Kannengiesser, C. & Fischer, A. Somatic genetic rescue in Mendelian haematopoietic diseases. Nat. Rev. Genet. https:\/\/doi.org\/10.1038\/s41576-019-0139-x (2019).","journal-title":"Nat. Rev. Genet."},{"key":"800_CR32","doi-asserted-by":"publisher","first-page":"6460","DOI":"10.1073\/pnas.85.17.6460","volume":"85","author":"O Danos","year":"1988","unstructured":"Danos, O. & Mulligan, R. C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl Acad. Sci. USA 85, 6460\u20136464 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nm0896-876","volume":"2","author":"H Hanenberg","year":"1996","unstructured":"Hanenberg, H. et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2, 876\u2013882 (1996).","journal-title":"Nat. Med."},{"key":"800_CR34","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood.V95.10.3071","volume":"95","author":"C Soudais","year":"2000","unstructured":"Soudais, C. et al. Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer. Blood 95, 3071\u20133077 (2000).","journal-title":"Blood"},{"key":"800_CR35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa012616","volume":"346","author":"S Hacein-Bey-Abina","year":"2002","unstructured":"Hacein-Bey-Abina, S. et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185\u20131193 (2002).","journal-title":"N. Engl. J. Med."},{"key":"800_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1056\/NEJMoa1000164","volume":"363","author":"S Hacein-Bey-Abina","year":"2010","unstructured":"Hacein-Bey-Abina, S. et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355\u2013364 (2010).","journal-title":"N. Engl. J. Med."},{"key":"800_CR37","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","volume":"364","author":"HB Gaspar","year":"2004","unstructured":"Gaspar, H. B. et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181\u20132187 (2004).","journal-title":"Lancet"},{"key":"800_CR38","doi-asserted-by":"publisher","first-page":"97ra79","DOI":"10.1126\/scitranslmed.3002715","volume":"3","author":"HB Gaspar","year":"2011","unstructured":"Gaspar, H. B. et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med. 3, 97ra79 (2011).","journal-title":"Sci. Transl. Med."},{"key":"800_CR39","doi-asserted-by":"publisher","first-page":"608653","DOI":"10.3389\/fimmu.2020.608653","volume":"11","author":"E Blanco","year":"2020","unstructured":"Blanco, E., Izotova, N., Booth, C. & Thrasher, A. J. Immune reconstitution after gene therapy approaches in patients with X-linked severe combined immunodeficiency disease. Front. Immunol. 11, 608653 (2020).","journal-title":"Front. Immunol."},{"key":"800_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaci.2020.05.055","volume":"146","author":"SY Pai","year":"2020","unstructured":"Pai, S. Y. & Thrasher, A. J. Gene therapy for X-linked severe combined immunodeficiency: historical outcomes and current status. J. Allergy Clin. Immunol. 146, 258\u2013261 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR41","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/nmeth1103","volume":"4","author":"M Schmidt","year":"2007","unstructured":"Schmidt, M. et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat. methods 4, 1051\u20131057 (2007).","journal-title":"Nat. methods"},{"key":"800_CR42","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1172\/JCI32949","volume":"117","author":"FD Bushman","year":"2007","unstructured":"Bushman, F. D. Retroviral integration and human gene therapy. J. Clin. Invest. 117, 2083\u20132086 (2007).","journal-title":"J. Clin. Invest."},{"key":"800_CR43","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1172\/JCI31659","volume":"117","author":"A Deichmann","year":"2007","unstructured":"Deichmann, A. et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117, 2225\u20132232 (2007).","journal-title":"J. Clin. Invest."},{"key":"800_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0580-z","volume":"10","author":"EL Clarke","year":"2018","unstructured":"Clarke, E. L. et al. T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. Genome Med. 10, 70 (2018).","journal-title":"Genome Med."},{"key":"800_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21834-9","volume":"12","author":"N Izotova","year":"2021","unstructured":"Izotova, N. et al. Long-term lymphoid progenitors independently sustain naive T and NK cell production in humans. Nat. Commun. 12, 1622 (2021).","journal-title":"Nat. Commun."},{"key":"800_CR46","doi-asserted-by":"publisher","first-page":"E6020","DOI":"10.1073\/pnas.1519118112","volume":"112","author":"MH Brugman","year":"2015","unstructured":"Brugman, M. H. et al. Development of a diverse human T-cell repertoire despite stringent restriction of hematopoietic clonality in the thymus. Proc. Natl Acad. Sci. USA 112, E6020\u2013E6027 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJM200301163480314","volume":"348","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina, S. et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255\u2013256 (2003).","journal-title":"N. Engl. J. Med."},{"key":"800_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina, S. et al. LMO2-associated clonal t cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415\u2013419 (2003).","journal-title":"Science"},{"key":"800_CR49","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1172\/JCI35798","volume":"118","author":"SJ Howe","year":"2008","unstructured":"Howe, S. J. et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143\u20133150 (2008).","journal-title":"J. Clin. Invest."},{"key":"800_CR50","first-page":"347","volume":"25","author":"E Six","year":"2017","unstructured":"Six, E. LMO2 associated clonal T cell proliferation 15 years after gamma-retrovirus gene therapy for SCIDX1. Mol. Ther. 25, 347\u2013348 (2017).","journal-title":"Mol. Ther."},{"key":"800_CR51","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina, S. et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132\u20133142 (2008).","journal-title":"J. Clin. Invest."},{"key":"800_CR52","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","volume":"363","author":"K Boztug","year":"2010","unstructured":"Boztug, K. et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918\u20131927 (2010).","journal-title":"N. Engl. J. Med."},{"key":"800_CR53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nm.2088","volume":"16","author":"S Stein","year":"2010","unstructured":"Stein, S. et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198\u2013204 (2010).","journal-title":"Nat. Med."},{"key":"800_CR54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ymthe.2020.11.020","volume":"29","author":"F Tucci","year":"2021","unstructured":"Tucci, F., Scaramuzza, S., Aiuti, A. & Mortellaro, A. Update on clinical ex vivo hematopoietic stem cell gene therapy for inherited monogenic diseases. Mol. Ther. 29, 489\u2013504 (2021).","journal-title":"Mol. Ther."},{"key":"800_CR55","first-page":"10-1097\/hs90000","volume":"5","author":"MP Cicalese","year":"2020","unstructured":"Cicalese, M. P. et al. Retroviral gene therapy for the treatment of ADA-SCID long-term follow up and first case of T-cell acute leukaemia due to insertional mutagenesis. Hemasphere 5, 10-1097\/hs90000000000000566 (2020).","journal-title":"Hemasphere"},{"key":"800_CR56","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/sj.mt.6300393","volume":"16","author":"SI Thornhill","year":"2008","unstructured":"Thornhill, S. I. et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol. Ther. 16, 590\u2013598 (2008).","journal-title":"Mol. Ther."},{"key":"800_CR57","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","volume":"371","author":"S Hacein-Bey-Abina","year":"2014","unstructured":"Hacein-Bey-Abina, S. et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N. Engl. J. Med. 371, 1407\u20131417 (2014).","journal-title":"N. Engl. J. Med."},{"key":"800_CR58","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/ni.3553","volume":"17","author":"F Vely","year":"2016","unstructured":"Vely, F. et al. Evidence of innate lymphoid cell redundancy in humans. Nat. Immunol. 17, 1291\u20131299 (2016).","journal-title":"Nat. Immunol."},{"key":"800_CR59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2108082118","author":"L Berteloot","year":"2021","unstructured":"Berteloot, L. et al. Alternative pathways for the development of lymphoid structures in humans. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2108082118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR60","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(04)16457-X","volume":"363","author":"C Laffort","year":"2004","unstructured":"Laffort, C. et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 363, 2051\u20132054 (2004).","journal-title":"Lancet"},{"key":"800_CR61","first-page":"291","volume":"35","author":"MS Hershfield","year":"1998","unstructured":"Hershfield, M. S. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin. Hematol. 35, 291\u2013298 (1998).","journal-title":"Semin. Hematol."},{"key":"800_CR62","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/blood-2011-12-396879","volume":"120","author":"A Hassan","year":"2012","unstructured":"Hassan, A. et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood 120, 3615\u20133624 (2012).","journal-title":"Blood"},{"key":"800_CR63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016196","author":"GDE Cuvelier","year":"2022","unstructured":"Cuvelier, G. D. E. et al. Outcomes following treatment for adenosine deaminase deficient severe combined immunodeficiency: a report from the PIDTC. Blood https:\/\/doi.org\/10.1182\/blood.2022016196 (2022).","journal-title":"Blood"},{"key":"800_CR64","first-page":"349","volume":"3","author":"C Booth","year":"2009","unstructured":"Booth, C. & Gaspar, H. B. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 3, 349\u2013358 (2009).","journal-title":"Biologics"},{"key":"800_CR65","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.270.5235.475","volume":"270","author":"RM Blaese","year":"1995","unstructured":"Blaese, R. M. et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270, 475\u2013480 (1995).","journal-title":"Science"},{"key":"800_CR66","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","volume":"101","author":"LM Muul","year":"2003","unstructured":"Muul, L. M. et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101, 2563\u20132569 (2003).","journal-title":"Blood"},{"key":"800_CR67","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1126\/science.270.5235.470","volume":"270","author":"C Bordignon","year":"1995","unstructured":"Bordignon, C. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 270, 470\u2013475 (1995).","journal-title":"Science"},{"key":"800_CR68","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nm0798-775","volume":"4","author":"DB Kohn","year":"1998","unstructured":"Kohn, D. B. et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat. Med. 4, 775\u2013780 (1998).","journal-title":"Nat. Med."},{"key":"800_CR69","first-page":"179","volume":"3","author":"PM Hoogerbrugge","year":"1996","unstructured":"Hoogerbrugge, P. M. et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 3, 179\u2013183 (1996).","journal-title":"Gene Ther."},{"key":"800_CR70","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa0805817","volume":"360","author":"A Aiuti","year":"2009","unstructured":"Aiuti, A. et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447\u2013458 (2009).","journal-title":"N. Engl. J. Med."},{"key":"800_CR71","doi-asserted-by":"publisher","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","volume":"3","author":"HB Gaspar","year":"2011","unstructured":"Gaspar, H. B. et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 3, 97ra80 (2011).","journal-title":"Sci. Transl. Med."},{"key":"800_CR72","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","volume":"120","author":"F Candotti","year":"2012","unstructured":"Candotti, F. et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120, 3635\u20133646 (2012).","journal-title":"Blood"},{"key":"800_CR73","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1172\/JCI31666","volume":"117","author":"A Aiuti","year":"2007","unstructured":"Aiuti, A. et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J. Clin. Invest. 117, 2233\u20132240 (2007).","journal-title":"J. Clin. Invest."},{"key":"800_CR74","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/emmm.201000108","volume":"3","author":"L Biasco","year":"2011","unstructured":"Biasco, L. et al. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol. Med. 3, 89\u2013101 (2011).","journal-title":"EMBO Mol. Med."},{"key":"800_CR75","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","volume":"384","author":"DB Kohn","year":"2021","unstructured":"Kohn, D. B. et al. Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency. N. Engl. J. Med. 384, 2002\u20132013 (2021).","journal-title":"N. Engl. J. Med."},{"key":"800_CR76","doi-asserted-by":"publisher","first-page":"1233151","DOI":"10.1126\/science.1233151","volume":"341","author":"A Aiuti","year":"2013","unstructured":"Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013).","journal-title":"Science"},{"key":"800_CR77","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","volume":"72","author":"R Zufferey","year":"1998","unstructured":"Zufferey, R. et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873\u20139880 (1998).","journal-title":"J. Virol."},{"key":"800_CR78","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809958","author":"L Naldini","year":"2019","unstructured":"Naldini, L. Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/emmm.201809958 (2019).","journal-title":"EMBO Mol. Med."},{"key":"800_CR79","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","volume":"380","author":"E Mamcarz","year":"2019","unstructured":"Mamcarz, E. et al. Lentiviral gene therapy combined with low-dose Busulfan in Infants with SCID-X1. N. Engl. J. Med. 380, 1525\u20131534 (2019).","journal-title":"N. Engl. J. Med."},{"key":"800_CR80","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1182\/blood-2004-12-4837","volume":"105","author":"AJ Thrasher","year":"2005","unstructured":"Thrasher, A. J. et al. Failure of SCID-X1 gene therapy in older patients. Blood 105, 4255\u20134257 (2005).","journal-title":"Blood"},{"key":"800_CR81","doi-asserted-by":"publisher","first-page":"335ra357","DOI":"10.1126\/scitranslmed.aad8856","volume":"8","author":"SS De Ravin","year":"2016","unstructured":"De Ravin, S. S. et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med. 8, 335ra357 (2016).","journal-title":"Sci. Transl. Med."},{"key":"800_CR82","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nri.2016.28","volume":"16","author":"LD Notarangelo","year":"2016","unstructured":"Notarangelo, L. D., Kim, M. S., Walter, J. E. & Lee, Y. N. Human RAG mutations: biochemistry and clinical implications. Nat. Rev. Immunol. 16, 234\u2013246 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"800_CR83","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jaci.2013.10.009","volume":"133","author":"NP van Til","year":"2014","unstructured":"van Til, N. P. et al. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. J. Allergy Clin. Immunol. 133, 1116\u20131123 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR84","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1038\/mt.2012.110","volume":"20","author":"NP van Til","year":"2012","unstructured":"van Til, N. P. et al. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. Mol. Ther. 20, 1968\u20131980 (2012).","journal-title":"Mol. Ther."},{"key":"800_CR85","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaci.2014.04.033","volume":"134","author":"K Pike-Overzet","year":"2014","unstructured":"Pike-Overzet, K. et al. Successful RAG1-SCID gene therapy depends on the level of RAG1 expression. J. Allergy Clin. Immunol. 134, 242\u2013243 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR86","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/mt.2008.118","volume":"16","author":"F Benjelloun","year":"2008","unstructured":"Benjelloun, F. et al. Stable and functional lymphoid reconstitution in Artemis-deficient mice following lentiviral Artemis gene transfer into hematopoietic stem cells. Mol. Ther. 16, 1490\u20131499 (2008).","journal-title":"Mol. Ther."},{"issue":"Suppl. 3","key":"800_CR87","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.bbmt.2019.12.589","volume":"26","author":"MJ Cowan","year":"2020","unstructured":"Cowan, M. J. et al. Early outcome of a phase I\/II clinical trial (NCT03538899) of gene-corrected autologous CD34+ hematopoietic cells and low-exposure busulfan in newly diagnosed patients with Artemis-deficient severe combined immunodeficiency (ART-SCID). Biol. Blood Marrow Transplant. 26 (Suppl. 3), S88\u2013S89 (2020).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"800_CR88","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1093\/hmg\/ddz170","volume":"28","author":"C Booth","year":"2019","unstructured":"Booth, C., Romano, R., Roncarolo, M. G. & Thrasher, A. J. Gene therapy for primary immunodeficiency. Hum. Mol. Genet. 28, R15\u2013R23 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"800_CR89","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nri2724","volume":"10","author":"AJ Thrasher","year":"2010","unstructured":"Thrasher, A. J. & Burns, S. O. WASP: a key immunological multitasker. Nat. Rev. Immunol. 10, 182\u2013192 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"800_CR90","doi-asserted-by":"publisher","first-page":"8697","DOI":"10.1073\/pnas.151260498","volume":"98","author":"T Wada","year":"2001","unstructured":"Wada, T. et al. Somatic mosaicism in Wiskott\u2013Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc. Natl Acad. Sci. USA 98, 8697\u20138702 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR91","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2019002939","volume":"135","author":"LM Burroughs","year":"2020","unstructured":"Burroughs, L. M. et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood 135, 2094\u20132105 (2020).","journal-title":"Blood"},{"key":"800_CR92","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood.2021014687","volume":"139","author":"MH Albert","year":"2022","unstructured":"Albert, M. H. et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood 139, 2066\u20132079 (2022).","journal-title":"Blood"},{"key":"800_CR93","doi-asserted-by":"publisher","first-page":"227ra233","DOI":"10.1126\/scitranslmed.3007280","volume":"6","author":"CJ Braun","year":"2014","unstructured":"Braun, C. J. et al. Gene therapy for Wiskott-Aldrich syndrome\u2013long-term efficacy and genotoxicity. Sci. Transl. Med. 6, 227ra233 (2014).","journal-title":"Sci. Transl. Med."},{"key":"800_CR94","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/jama.2015.3253","volume":"313","author":"S Hacein-Bey Abina","year":"2015","unstructured":"Hacein-Bey Abina, S. et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA 313, 1550\u20131563 (2015).","journal-title":"JAMA"},{"key":"800_CR95","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","volume":"6","author":"F Ferrua","year":"2019","unstructured":"Ferrua, F. et al. Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study. Lancet Haematol. 6, e239\u2013e253 (2019).","journal-title":"Lancet Haematol."},{"issue":"Suppl. 1","key":"800_CR96","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1182\/blood-2019-126161","volume":"134","author":"E Labrosse","year":"2019","unstructured":"Labrosse, E. et al. Outcome of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood 134 (Suppl. 1), 4629 (2019).","journal-title":"Blood"},{"key":"800_CR97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41591-021-01641-x","volume":"28","author":"A Magnani","year":"2022","unstructured":"Magnani, A. et al. Long-term safety and efficacy of lentiviral hematopoietic stem\/progenitor cell gene therapy for Wiskott-Aldrich syndrome. Nat. Med. 28, 71\u201380 (2022).","journal-title":"Nat. Med."},{"key":"800_CR98","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jaci.2019.03.012","volume":"144","author":"L Sereni","year":"2019","unstructured":"Sereni, L. et al. Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome. J. Allergy Clin. Immunol. 144, 825\u2013838 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR99","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2017-04-777136","volume":"130","author":"EC Morris","year":"2017","unstructured":"Morris, E. C. et al. Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. Blood 130, 1327\u20131335 (2017).","journal-title":"Blood"},{"key":"800_CR100","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41591-018-0195-3","volume":"24","author":"S Scala","year":"2018","unstructured":"Scala, S. et al. Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans. Nat. Med. 24, 1683\u20131690 (2018).","journal-title":"Nat. Med."},{"key":"800_CR101","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1182\/blood.2019002350","volume":"135","author":"E Six","year":"2020","unstructured":"Six, E. et al. Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs. Blood 135, 1219\u20131231 (2020).","journal-title":"Blood"},{"key":"800_CR102","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12016-009-8136-z","volume":"38","author":"SM Holland","year":"2018","unstructured":"Holland, S. M. Chronic granulomatous disease. Clin. Rev. Allergy Immunol. 38, 3\u201310 (2018).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"800_CR103","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fped.2020.00327","volume":"8","author":"T Gungor","year":"2020","unstructured":"Gungor, T. & Chiesa, R. Cellular therapies in chronic granulomatous disease. Front. Pediatr. 8, 327 (2020).","journal-title":"Front. Pediatr."},{"key":"800_CR104","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","volume":"26","author":"DB Kohn","year":"2020","unstructured":"Kohn, D. B. et al. Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat. Med. 26, 200\u2013206 (2020).","journal-title":"Nat. Med."},{"key":"800_CR105","first-page":"56","volume":"28","author":"DB Kohn","year":"2020","unstructured":"Kohn, D. B. Phase 1\/2 study of lentiviral-mediated ex-vivo gene therapy for pediatrics patients with severe leukocyte adhesion deficiency-I (LAD-I): initial results from the first treated patient. Mol. Ther. 28, 56 (2020).","journal-title":"Mol. Ther."},{"key":"800_CR106","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1182\/blood-2016-07-729871","volume":"128","author":"T Soheili","year":"2016","unstructured":"Soheili, T. et al. Gene-corrected human Munc13-4-deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice. Blood 128, 2859\u20132862 (2016).","journal-title":"Blood"},{"key":"800_CR107","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jaci.2018.02.053","volume":"142","author":"N Panchal","year":"2018","unstructured":"Panchal, N. et al. Transfer of gene-corrected T cells corrects humoral and cytotoxic defects in patients with X-linked lymphoproliferative disease. J. Allergy Clin. Immunol. 142, 235\u2013245 e236 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR108","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaci.2017.11.050","volume":"142","author":"S Ghosh","year":"2018","unstructured":"Ghosh, S. et al. T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations. J. Allergy Clin. Immunol. 142, 904\u2013913 e903 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR109","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330\u2013336 (2003).","journal-title":"Nat. Immunol."},{"key":"800_CR110","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","volume":"141","author":"F Barzaghi","year":"2018","unstructured":"Barzaghi, F. et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. J. Allergy Clin. Immunol. 141, 1036\u20131049 e1035 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR111","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/eji.202149210","volume":"52","author":"S Borna","year":"2022","unstructured":"Borna, S., Lee, E., Sato, Y. & Bacchetta, R. Towards gene therapy for IPEX syndrome. Eur. J. Immunol. 52, 705\u2013716 (2022).","journal-title":"Eur. J. Immunol."},{"key":"800_CR112","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.stem.2018.12.003","volume":"24","author":"KE Masiuk","year":"2019","unstructured":"Masiuk, K. E., Laborada, J., Roncarolo, M. G., Hollis, R. P. & Kohn, D. B. Lentiviral gene therapy in HSCs restores lineage-specific Foxp3 expression and suppresses autoimmunity in a mouse model of IPEX syndrome. Cell Stem Cell 24, 309\u2013317 e307 (2019).","journal-title":"Cell Stem Cell"},{"key":"800_CR113","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1182\/blood.2020009187","volume":"137","author":"M Delville","year":"2021","unstructured":"Delville, M. et al. A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control scurfy syndrome. Blood 137, 2326\u20132336 (2021).","journal-title":"Blood"},{"key":"800_CR114","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini, L. Gene therapy returns to centre stage. Nature 526, 351\u2013360 (2015).","journal-title":"Nature"},{"key":"800_CR115","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","volume":"22","author":"G Ferrari","year":"2021","unstructured":"Ferrari, G., Thrasher, A. J. & Aiuti, A. Gene therapy using haematopoietic stem and progenitor cells. Nat. Rev. Genet. 22, 216\u2013234 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"800_CR116","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","volume":"133","author":"HS Kwon","year":"2019","unstructured":"Kwon, H. S. et al. Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. Blood 133, 2104\u20132108 (2019).","journal-title":"Blood"},{"key":"800_CR117","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jaci.2020.04.033","volume":"147","author":"MC Castiello","year":"2021","unstructured":"Castiello, M. C. et al. Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency. J. Allergy Clin. Immunol. 147, 309\u2013320 e306 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"800_CR118","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.cell.2022.04.039","volume":"185","author":"A Omer-Javed","year":"2022","unstructured":"Omer-Javed, A. et al. Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells. Cell 185, 2248\u20132264 e2221 (2022).","journal-title":"Cell"},{"key":"800_CR119","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229\u2013236 (2020).","journal-title":"Nature"},{"key":"800_CR120","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMra1800729","volume":"380","author":"MH Porteus","year":"2019","unstructured":"Porteus, M. H. A new class of medicines through DNA editing. N. Engl. J. Med. 380, 947\u2013959 (2019).","journal-title":"N. Engl. J. Med."},{"key":"800_CR121","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N. Engl. J. Med. 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med."},{"key":"800_CR122","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature13420","volume":"510","author":"P Genovese","year":"2014","unstructured":"Genovese, P. et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510, 235\u2013240 (2014).","journal-title":"Nature"},{"key":"800_CR123","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0820","author":"G Schiroli","year":"2017","unstructured":"Schiroli, G. et al. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan0820 (2017).","journal-title":"Sci. Transl. Med."},{"key":"800_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09614-y","volume":"10","author":"M Pavel-Dinu","year":"2019","unstructured":"Pavel-Dinu, M. et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat. Commun. 10, 1634 (2019).","journal-title":"Nat. Commun."},{"key":"800_CR125","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s10875-021-00989-6","volume":"41","author":"CL Gardner","year":"2021","unstructured":"Gardner, C. L. et al. Gene editing rescues in vitro T cell development of RAG2-deficient induced pluripotent stem cells in an artificial thymic organoid system. J. Clin. Immunol. 41, 852\u2013862 (2021).","journal-title":"J. Clin. Immunol."},{"key":"800_CR126","doi-asserted-by":"publisher","first-page":"eaaz0571","DOI":"10.1126\/sciadv.aaz0571","volume":"6","author":"M Goodwin","year":"2020","unstructured":"Goodwin, M. et al. CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells. Sci. Adv. 6, eaaz0571 (2020).","journal-title":"Sci. Adv."},{"key":"800_CR127","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood-2015-11-683235","volume":"127","author":"N Hubbard","year":"2016","unstructured":"Hubbard, N. et al. Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome. Blood 127, 2513\u20132522 (2016).","journal-title":"Blood"},{"key":"800_CR128","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013545","volume":"13","author":"V Vavassori","year":"2021","unstructured":"Vavassori, V. et al. Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome. EMBO Mol. Med. 13, e13545 (2021).","journal-title":"EMBO Mol. Med."},{"key":"800_CR129","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/j.celrep.2018.04.103","volume":"23","author":"CY Kuo","year":"2018","unstructured":"Kuo, C. Y. et al. Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome. Cell Rep. 23, 2606\u20132616 (2018).","journal-title":"Cell Rep."},{"key":"800_CR130","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1182\/blood.2021011192","volume":"138","author":"J Brault","year":"2021","unstructured":"Brault, J. et al. CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes. Blood 138, 2768\u20132780 (2021).","journal-title":"Blood"},{"key":"800_CR131","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/crispr.2020.0080","volume":"4","author":"DH Gray","year":"2021","unstructured":"Gray, D. H. et al. Optimizing integration and expression of transgenic Bruton\u2019s tyrosine kinase for CRISPR-Cas9-mediated gene editing of x-linked agammaglobulinemia. CRISPR J. 4, 191\u2013206 (2021).","journal-title":"CRISPR J."},{"key":"800_CR132","doi-asserted-by":"publisher","first-page":"eabn5811","DOI":"10.1126\/scitranslmed.abn5811","volume":"14","author":"TA Fox","year":"2022","unstructured":"Fox, T. A. et al. Therapeutic gene editing of T cells to correct CTLA-4 insufficiency. Sci. Transl. Med. 14, eabn5811 (2022).","journal-title":"Sci. Transl. Med."},{"key":"800_CR133","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41587-020-0551-y","volume":"38","author":"S Ferrari","year":"2020","unstructured":"Ferrari, S. et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat. Biotechnol. 38, 1298\u20131308 (2020).","journal-title":"Nat. Biotechnol."},{"key":"800_CR134","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1182\/blood.2020008503","volume":"137","author":"SS De Ravin","year":"2021","unstructured":"De Ravin, S. S. et al. Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem\/progenitor cells. Blood 137, 2598\u20132608 (2021).","journal-title":"Blood"},{"key":"800_CR135","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41434-021-00251-z","volume":"28","author":"CL Sweeney","year":"2021","unstructured":"Sweeney, C. L. et al. Correction of X-CGD patient HSPCs by targeted CYBB cDNA insertion using CRISPR\/Cas9 with 53BP1 inhibition for enhanced homology-directed repair. Gene Ther. 28, 373\u2013390 (2021).","journal-title":"Gene Ther."},{"key":"800_CR136","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nbt.4021","volume":"36","author":"MD Canny","year":"2018","unstructured":"Canny, M. D. et al. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. Nat. Biotechnol. 36, 95\u2013102 (2018).","journal-title":"Nat. Biotechnol."},{"key":"800_CR137","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1016\/j.ymthe.2021.09.002","volume":"29","author":"GA Newby","year":"2021","unstructured":"Newby, G. A. & Liu, D. R. In vivo somatic cell base editing and prime editing. Mol. Ther. 29, 3107\u20133124 (2021).","journal-title":"Mol. Ther."},{"key":"800_CR138","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"800_CR139","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"800_CR140","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","volume":"26","author":"J Zeng","year":"2020","unstructured":"Zeng, J. et al. Therapeutic base editing of human hematopoietic stem cells. Nat. Med. 26, 535\u2013541 (2020).","journal-title":"Nat. Med."},{"key":"800_CR141","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.ymthe.2021.09.001","volume":"29","author":"BC Lee","year":"2021","unstructured":"Lee, B. C., Lozano, R. J. & Dunbar, C. E. Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells. Mol. Ther. 29, 3205\u20133218 (2021).","journal-title":"Mol. Ther."},{"key":"800_CR142","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","volume":"16","author":"CL Lucas","year":"2016","unstructured":"Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M. & Okkenhaug, K. PI3Kdelta and primary immunodeficiencies. Nat. Rev. Immunol. 16, 702\u2013714 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"800_CR143","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/ACI.0000000000000401","volume":"17","author":"RD Jhamnani","year":"2017","unstructured":"Jhamnani, R. D. & Rosenzweig, S. D. An update on gain-of-function mutations in primary immunodeficiency diseases. Curr. Opin. Allergy Clin. Immunol. 17, 391\u2013397 (2017).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"800_CR144","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.coi.2017.10.001","volume":"49","author":"F Rieux-Laucat","year":"2017","unstructured":"Rieux-Laucat, F. What\u2019s up in the ALPS. Curr. Opin. Immunol. 49, 79\u201386 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"800_CR145","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41591-019-0676-z","volume":"25","author":"A Fischer","year":"2019","unstructured":"Fischer, A., Dewatripont, M. & Goldman, M. Benefit corporation: a path to affordable gene therapies. Nat. Med. 25, 1813\u20131814 (2019).","journal-title":"Nat. Med."},{"key":"800_CR146","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41591-021-01481-9","volume":"27","author":"Editorial.","year":"2021","unstructured":"Editorial. Gene therapies should be for all. Nat. Med. 27, 1311 (2021).","journal-title":"Nat. Med."},{"key":"800_CR147","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1073\/pnas.91.13.6064","volume":"91","author":"P Rouet","year":"1994","unstructured":"Rouet, P., Smih, F. & Jasin, M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc. Natl Acad. Sci. USA 91, 6064\u20136068 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"800_CR148","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nature03556","volume":"435","author":"FD Urnov","year":"2005","unstructured":"Urnov, F. D. et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646\u2013651 (2005).","journal-title":"Nature"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-022-00800-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-022-00800-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-022-00800-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T09:04:46Z","timestamp":1685523886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-022-00800-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":148,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1038\/s41577-022-00800-6","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"26 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}